A1V0 Stock Overview
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aptorum Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.08 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$3.29 |
| Beta | -0.019 |
| 1 Month Change | 0% |
| 3 Month Change | -9.94% |
| 1 Year Change | -72.04% |
| 3 Year Change | -88.61% |
| 5 Year Change | n/a |
| Change since IPO | -97.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| A1V0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -72.0% | -19.9% | 0.9% |
Return vs Industry: A1V0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: A1V0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| A1V0 volatility | |
|---|---|
| A1V0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A1V0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A1V0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 19 | Darren Lui | www.aptorumgroup.com |
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity.
Aptorum Group Limited Fundamentals Summary
| A1V0 fundamental statistics | |
|---|---|
| Market cap | €12.37m |
| Earnings (TTM) | -€9.14m |
| Revenue (TTM) | €1.21m |
10.2x
P/S Ratio-1.4x
P/E RatioIs A1V0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A1V0 income statement (TTM) | |
|---|---|
| Revenue | US$1.30m |
| Cost of Revenue | US$1.22m |
| Gross Profit | US$80.07k |
| Other Expenses | US$9.88m |
| Earnings | -US$9.80m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.35 |
| Gross Margin | 6.18% |
| Net Profit Margin | -756.20% |
| Debt/Equity Ratio | 83.1% |
How did A1V0 perform over the long term?
See historical performance and comparison